![Johnson & Johnson Vice President and Worldwide Chairman Pharmaceuticals Joaquin Duato (L-R), Actelion CEO and founder Jean-Paul Clozel and Johnson & Johnson Chief Scientific Officer Pharmaceuticals Paul Stoffels pose for photographers at ... Johnson & Johnson Vice President and Worldwide Chairman Pharmaceuticals Joaquin Duato (L-R), Actelion CEO and founder Jean-Paul Clozel and Johnson & Johnson Chief Scientific Officer Pharmaceuticals Paul Stoffels pose for photographers at ...](https://c8.alamy.com/zooms/6/3035ec778e5843aa8f8088a732d91741/2cjce8r.jpg)
Johnson & Johnson Vice President and Worldwide Chairman Pharmaceuticals Joaquin Duato (L-R), Actelion CEO and founder Jean-Paul Clozel and Johnson & Johnson Chief Scientific Officer Pharmaceuticals Paul Stoffels pose for photographers at ...
![Swiss biotech Actelion CEO Jean-Paul Clozel endorses independence not acquisition - CEOWORLD magazine Swiss biotech Actelion CEO Jean-Paul Clozel endorses independence not acquisition - CEOWORLD magazine](https://ceoworld.biz/wp-content/uploads/2011/01/Jean-Paul-Clozel-Actelion.jpg)
Swiss biotech Actelion CEO Jean-Paul Clozel endorses independence not acquisition - CEOWORLD magazine
![Johnson & Johnson Chief Scientific Officer Pharmaceuticals Paul Stoffels (L) and Actelion CEO and founder Jean-Paul Clozel attend a news conference at Actelion headquarters in Allschwil, Switzerland January 26, 2017. REUTERS/Arnd Wiegmann Stock ... Johnson & Johnson Chief Scientific Officer Pharmaceuticals Paul Stoffels (L) and Actelion CEO and founder Jean-Paul Clozel attend a news conference at Actelion headquarters in Allschwil, Switzerland January 26, 2017. REUTERS/Arnd Wiegmann Stock ...](https://c8.alamy.com/zooms/6/de6a70debb33428883bdf86b036d015c/2crgbyc.jpg)
Johnson & Johnson Chief Scientific Officer Pharmaceuticals Paul Stoffels (L) and Actelion CEO and founder Jean-Paul Clozel attend a news conference at Actelion headquarters in Allschwil, Switzerland January 26, 2017. REUTERS/Arnd Wiegmann Stock ...
![Actelion spinout Idorsia hits goals in insomnia phase 2, sparking stock rise and talk of partnering up for pivotal trial | Fierce Biotech Actelion spinout Idorsia hits goals in insomnia phase 2, sparking stock rise and talk of partnering up for pivotal trial | Fierce Biotech](https://qtxasset.com/quartz/qcloud5/media/image/2017-07/jean-paul-clozel.jpg?VersionId=XgbOevldywLeshp5Jmr7FuRH1aT38Vu4)